Xenon PharmaceuticalsXENE
Recorded

Xenon Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration29 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Delma CaiatiResearch Analyst

Good morning, everybody, and welcome back at our Guggenheim Healthcare Innovation Conference. I am Delma Caiati, one of the research analysts here at Guggenheim, and it's my pleasure to introduce our next company, Xenon Pharmaceuticals. From the company, we have Tucker Kelly, the CFO, and it's a pleasure to have you here, Tucker. Maybe, before going into the Q&A, you just released the third quarter financial results, so why don't you give us the latest update on the company, and then we'll move on from there?

Tucker KellyCFO

Sure. First of all, Delma, thank you and Guggenheim for hosting us at the conference this year. It's great to be here in Boston with an awesome group of investors. Things at Xenon are going incredibly well right now. For those of you who aren't familiar with Xenon, we're an ion channel company. We've got capabilities from drug discovery and research, and we're on the cusp of becoming a commercial company for the first time in our history. We filed our NDA in September, and we look forward to commercializing in the U.S. the drug called azetukalner for focal seizures. Beyond that, we've got expansion opportunities in neuropsychiatry. We've got ongoing studies in major depressive disorder, one of which we announced last night on the Q3 earnings call.

Tucker KellyCFO

We've been able to move up the readout for that study into December of this year, as well as a phase III study in bipolar depression. Beyond that, we just had recent data that we touched on in the Q3 call last night that we can dive into as well, Delma, around our early-stage pain programs. We have three in the clinic now. Two are targeted against a sodium channel called NaV1.7, and another is a KV7 target, which is the same one we have for azetukalner for focal seizures. We just had phase I data for two of those at the World Congress on Pain for the IASP Conference in Thailand.

Tucker KellyCFO

A lot going on on the clinical side, and we've got an early active research program as well, one focused around NaV1.1 for Dravet syndrome, and a partner program that's in the clinic today with Neurocrine against NaV1.2 and 1.6. We're well capitalized. We have $1.2 billion in cash and cash into 2029. So, we're really at a kind of transformative time, and look forward to some big milestones coming up over the next year and a half, two years.

Delma CaiatiResearch Analyst

Thank you for that great overview, and clearly a lot to unpack there. Let's start with the epilepsy programs. As you said, you submitted the NDA in September, and we expect approval in the upcoming months. When we think about the label, how will that look like? What is your base case scenario for the label? When you think about the value proposition of the drug, of azetukalner, how will it be used in real-world clinical practice?

Tucker KellyCFO

Sure. Let me weave those two together, because I think they are related and relevant. We think azetukalner can be a really impactful drug in focal seizures. This is an area of high unmet medical need, even though there are a large number of agents that are approved today, most of which are generic. There is only one branded left. There is still first, a large group of patients that have breakthrough seizures that are not adequately well controlled, and that is consistent with the trial population. In the phase III and registration study in the phase IIb, we saw very refractory patients. They had been on five or six different ASMs, and they were, during the study, on two or three anti-seizure medications as well. In focal onset seizures, the labels are very broad, so you do not get line of therapy type labels.

Tucker KellyCFO

It will be a broad label for focal seizures, and we think that gives us the opportunity to start with patients who are more refractory, who are seen by epileptologists, and really need quick seizure control to help them get their disease more under control, but to then move over time into earlier line patients. That goes to another update we had on the Q3 call last night, where we are going to be opening a phase IIIb/IV study looking at what we call patients with a first add-on. These are patients with epilepsy that, when you are newly diagnosed, you usually go on one of two different types of agents as a monotherapy. Oftentimes, you will take generic KEPPRA as an SV2A modulator or a sodium channel blocker, and then you will kind of flip-flop. If you are not well controlled on one, you will maybe move to the other.

Tucker KellyCFO

At that point, if you are not really well treated, most often you go to a kind of polypharmacy approach, and you get a first add-on.

Tucker KellyCFO

That is where patients and physicians are really trying to get a hold of the seizure control in a different way. We think that ultimately, we can provide a really impactful benefit in those earlier line patients and move from the more refractory later line patients that will likely start with a launch up until those earlier line patients. In a heavily genericized market and an area where KEPPRA and other drugs have served patients so well, a lot of patients are effectively treated when they go on a monotherapy SV2A, and they do not ever need to get there. So we think ultimately, first line is likely still the reserve for generics that people do well on, but that first add-on could be a way for us to make this a really impactful large drug in the class.

Delma CaiatiResearch Analyst

Yeah, that is actually a very interesting update that you add. I was wondering, so that is going to be an open-label study. Does it give you the opportunity to include the data also in Section 14 of the label?

Tucker KellyCFO

Yeah, not clear that it would be label enabling or expanding the label. We think it will provide good scientific evidence of what activity looks like in earlier line patients. We think that is particularly important for general neurologists. As we talked about on the call last night, we think it is also an opportunity to involve a broader range of physicians in the clinical development of azetukalner, that includes general neurologists as well. So not necessarily expanding the label with an open-label study, but we do think it can be impactful and helpful in terms of being able to look at what the drug can do for patients that are not as refractory.

Delma CaiatiResearch Analyst

Are you planning to show any interim data before the topline?

Tucker KellyCFO

Yeah, we'll provide more details on the study design. Last night, we just kind of debuted the high-level overview of what we want to do in the study. We'll talk a little bit more about the details going forward. We'll have a big presence at AES. That's the annual American Epilepsy Society meeting coming up in Denver in December, and we wanted to get this news out ahead of that so we can really start to talk with physicians and build some momentum around enrolling that study in the first half of next year.

Delma CaiatiResearch Analyst

Got it. Since you mentioned the AES, what should we expect from the data there? You always have a very large presentation, number of presentations.

Tucker KellyCFO

We do, yeah. We continue to increase our presence as a company as we mature, and again, on the cusp of being a commercial company, we'll have our largest presence ever at AES. That's both on the conference room floor with our booth, with our medical affairs team, and doing things like talking to physicians about potential enrollment in studies like X-FIRST. But also just continuing to build disease state awareness, to talk more about mechanism. That's one of the key things about ezogabine that's different. We have a novel way of approaching anti-seizure medications. We'll be the first KV7 potassium channel modulator on the market here in the U.S. now, if we're able to get approval. We'll have a big presence at AES. In addition, we've been, I think, very active on the clinical front in terms of putting out additional data.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day